KRAS and neoplasm: In the F3008 model, when compared to adagrasib treatment alone, treatment with adagrasib plus BI-3406 or cetuximab resulted in a strong downregulation of KRAS and MRAS expression (Extended Data Fig. 5e), suggesting durable inhibition of MAPK pathway signaling in residual tumor cells.